WATSON Laboratories has
received US Food and Drug
Administration approval for its
diclofenac sodium and misoprostol
delayed-release tablets, the generic
equivalent to G.D. Searle's
Arthrotec.
The tablets are indicated for the
treatment of the signs and
symptoms of osteoarthritis or
rheumatoid arthritis in patients at
high risk of developing NSAIDinduced
gastric and duodenal
ulcers and their complications.
Watson now plans to launch the
product in the fourth quarter of
2012.
See www.fda.gov for details.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Jul 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Jul 12
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.